Absence of tobramycin pharmacokinetic and creatinine clearance variation during the menstrual cycle: implied absence of variation in glomerular filtration rate.
During the menstrual cycle, a 20% increase in creatinine clearance (CL(CR] has previously been reported between the menstrual (phase 1) and late luteal (phase 4) phases. Tobramycin pharmacokinetics and CL(CR) were studied in eight healthy women with documented, regular, ovulatory menses. During the first and fourth phases of the menstrual cycle (as determined by urinary luteinizing hormone peak and basal body temperature shift), subjects received tobramycin by intravenous bolus. Tobramycin half-life, total body clearance, and volume of distribution were not significantly different between the two study phases. No significant change in total urinary creatinine excretion or CL(CR) was seen between phases. Total 24 hour urinary recovery of tobramycin was 98-99.7%. We conclude that no significant changes in renal function, as evaluated by tobramycin pharmacokinetics and CL(CR), occur between these hormonally different phases of the menstrual cycle, and that urinary recovery of a single dose of tobramycin is nearly complete within 24 hours in premenopausal women with normal renal function.
Research Institute Mary Imogene Bassett Hospital, Cooperstown, NY 13326.
A N
AN
Nafziger
M S
MS
Schwartzman
J S
JS
Bertino
D000328:Adult; D001831:Body Temperature; D003404:Creatinine / Q000097:blood* / Q000652:urine; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle; D014031:Tobramycin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D007986:Luteinizing Hormone; D003404:Creatinine; D014031:Tobramycin